Louisiana State Employees Retirement System Takes Position in Arcus Biosciences, Inc. (NYSE:RCUS)

Louisiana State Employees Retirement System acquired a new position in Arcus Biosciences, Inc. (NYSE:RCUS) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 27,000 shares of the company’s stock, valued at approximately $516,000.

Several other large investors have also modified their holdings of RCUS. Alps Advisors Inc. raised its holdings in Arcus Biosciences by 2.3% in the 3rd quarter. Alps Advisors Inc. now owns 54,951 shares of the company’s stock worth $986,000 after acquiring an additional 1,214 shares during the period. Arizona State Retirement System increased its stake in shares of Arcus Biosciences by 10.0% in the third quarter. Arizona State Retirement System now owns 13,530 shares of the company’s stock worth $243,000 after purchasing an additional 1,226 shares during the period. Principal Financial Group Inc. lifted its position in shares of Arcus Biosciences by 0.4% during the 3rd quarter. Principal Financial Group Inc. now owns 329,442 shares of the company’s stock worth $5,913,000 after purchasing an additional 1,312 shares during the last quarter. BluePath Capital Management LLC bought a new stake in Arcus Biosciences during the 3rd quarter valued at approximately $28,000. Finally, Teacher Retirement System of Texas grew its holdings in Arcus Biosciences by 13.6% in the 3rd quarter. Teacher Retirement System of Texas now owns 13,496 shares of the company’s stock valued at $242,000 after buying an additional 1,613 shares during the last quarter. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Trading Up 0.5 %

RCUS stock opened at $15.63 on Tuesday. Arcus Biosciences, Inc. has a 1-year low of $12.95 and a 1-year high of $25.47. The business’s 50 day moving average is $17.46 and its 200-day moving average is $16.61. The firm has a market cap of $1.42 billion, a P/E ratio of -3.77 and a beta of 0.81.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.01. Arcus Biosciences had a negative return on equity of 57.17% and a negative net margin of 262.39%. The firm had revenue of $31.00 million for the quarter, compared to analysts’ expectations of $28.30 million. During the same period in the prior year, the business posted ($0.93) earnings per share. The business’s revenue was down 8.8% compared to the same quarter last year. Sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.59 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on RCUS shares. Mizuho cut their price target on Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a report on Tuesday, January 30th. Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Arcus Biosciences in a report on Thursday, February 22nd. Finally, Truist Financial restated a “buy” rating and set a $50.00 price objective on shares of Arcus Biosciences in a report on Monday, March 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average target price of $41.25.

Insider Transactions at Arcus Biosciences

In related news, COO Jennifer Jarrett sold 24,555 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $20.07, for a total transaction of $492,818.85. Following the sale, the chief operating officer now directly owns 274,323 shares in the company, valued at approximately $5,505,662.61. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, COO Jennifer Jarrett sold 24,555 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $20.07, for a total value of $492,818.85. Following the transaction, the chief operating officer now directly owns 274,323 shares in the company, valued at approximately $5,505,662.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Juan C. Jaen sold 3,900 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $20.06, for a total value of $78,234.00. Following the transaction, the president now owns 1,211,365 shares of the company’s stock, valued at $24,299,981.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,455 shares of company stock valued at $1,014,779. Corporate insiders own 13.80% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.